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Abstract
Background—Common variation in the Fat Mass and Obesity related (FTO) gene is associated
with increased body fat and susceptibility to type 2 diabetes (T2D). We hypothesized that this
would also associate with metabolic phenotypes of insulin resistance, and increased risk of
cardiovascular morbidity and mortality.
Methods and Results—FTO rs9939609 genotype was determined in 4897 patients with T2D
in the prospective Genetics of Diabetes Audit and Research Study in Tayside Scotland (Go-
DARTS) study. The A allele was associated with lower plasma HDL cholesterol (mean difference
0.03 mmol/L, p=0.008), higher triglycerides (0.1 mmol/L, p=0.007), higher atherogenic index of
plasma (0.03, p=0.003) and, as expected, increased BMI (0.77 kg/m2, p=8.8×10−6). During a
mean follow up of 3.6 years the A allele was also associated with increased risk (HR 2.36, CI
1.49-3.74, p=0.0002) of fatal and non fatal myocardial infarction (total 324 events) in a model
including baseline age, gender, prevalent myocardial infarction, smoking status, statin and insulin
use. This association diminished but remained significant when obesity related traits such as BMI,
glycated haemoglobin and lipid parameters were also included (HR 2.01 CI 1.18-3.45, p=0.011).
There was a strong interaction of FTO genotype and statin use and cardiovascular outcome
(p=0.001) such that cardiovascular morbidity and mortality was completely abrogated in
individuals prescribed statins.
Conclusion—The increased fat mass in carriers of the A allele of rs9939609 of FTO is
associated not only with increased risk of T2D, but also with an increase in atherogenic lipid
profile, and myocardial infarction in these patients. This variant may therefore in future contribute
to more effective targeting of specific preventative therapy.
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Introduction
The increasing global burden of obesity is associated with an increasing prevalence of type 2
diabetes (T2D) and subsequently an increase in morbidity and mortality primarily due to
ischemic heart disease1. It has been estimated that for every increase in a BMI measure of
one unit there is an 8% increase in cardiovascular mortality2. Recently whole genome
association studies have demonstrated that SNP rs9939609 in the Fat Mass and Obesity
associated gene region (FTO) at 16q10 is strongly associated with both increased body
weight and also susceptibility to T2D3 and this association has been confirmed in other
studies4,5. The original association with T2D was found to be through an association with
body mass index (BMI). Other SNPs in this region have also been identified with similar
associations and it seems likely that their association is due to linkage disequilibrium within
the region4. While the SNPs seem to be associated with raised BMI in multiple European
populations3,4, the association appears to be absent in some non-European populations such
as the African Americans4 the Chinese Han 6 and in oceanic populations7. It has been
demonstrated that the region is also associated with other metabolic features related to being
over weight. Healthy individuals possessing the A allele were found not only to have a
raised body mass index but also an increased whole body resistance to insulin8. Given the
firmly established relationship of increased BMI and T2D with cardiovascular morbidity and
mortality we investigated the clinical impact of genetic variation in the FTO gene terms of
risk of myocardial infarction in a large population of patients with T2D in Scotland known
as Go-DARTS.
Methods
The Go-DARTS population has been described in previous studies9-11 and has been
collected from the Tayside region of Scotland (population approximately 400,000) where all
healthcare activity has, for the past 2 decades, been linked to a patient-unique identifier
facilitating the creation of sophisticated regional health informatics systems. The Diabetes
Audit and Research in Tayside Study (DARTS) is a comprehensive, well validated, region-
wide clinical information system containing detailed data on effectively all patients with
diabetes in the region12. The data is assimilated from multiple resources including the
Community Health Index (CHI) which contains demographic data, Scottish Morbidity
Records (SMR) detailing ICD (International Classification of Disease) coding for hospital
admissions, with data from the General Registrars Office (GRO) detailing date and cause of
death and general practitioner office records. Data has been verified through a continuous
research nurse-led validation process. Other data sources include the regional biochemistry
database containing all historical serum biochemistry assays and the regional dispensed
prescribing database maintained by the University of Dundee’s Health Informatics Centre.
This contains historical data on all medicines prescribed for all individuals in the region
from 1993 to present.
Over the past 10 years an increasing number of patients with T2D in the region have been
approached to provide a sample of blood for genetic studies with consent for the genetic
information to be linked anonymously to their clinical data in DARTS and associated data
sets. Many of these individuals were recruited under the auspices of the Wellcome Trust UK
type 2 Diabetes Case Control consortium and contributed significantly to the replication
phase for the WTCCC GWA studies for T2D3. The linkage of this genotypic data from this
large group of patients with T2D together with the rich longitudinal clinical datasets
constitutes the Genetics of DARTS (Go-DARTS) study. We studied 4786 individuals with a
diagnosis of T2D who were recruited to Go-DARTS between October 1997 and March 2006
and with an age of recruitment less than 85 years of age.
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Genotyping
Genotyping of rs9939609 was performed as previously described using a combination of
TAQMAN allelic discrimination and KASPAR genotyping (Kbiosciences)13.
Statistics
Each individual in Go-DARTS often has multiple measures of clinical parameters recorded
over a period of time during the course of their clinical management. We therefore obtained
a single integrated estimate as a mean value of multiple measures for each individual (intra-
individual mean), obtained within a three year period around the date the individual was
recruited into the Go-DARTS study. These clinical parameters were Body Mass Index, total
Cholesterol, HDL cholesterol, triglycerides, glycated hemoglobin, systolic and diastolic
blood pressure. All such intra-individual mean values were adjusted for age and gender. In
the case of triglycerides and triglyceride-related values which can vary widely depending on
post-prandial state, intra-individual means were also adjusted for intra-individual variation
as the standard deviation of the intra-individual range. Atherogenic index of plasma14 was
determined by log10([Triglycerides]/[HDLc]). Analysis of variance was used to determine
the impact of genotype on clinical parameters.
In order to perform a prospective study of the impact of the FTO variant on cardiovascular
disease in T2D we studied only individuals who had at least 1 year of follow up data from
recruitment to the genetic study with Cox’s regression being used to estimate the relative
rates of cardiovascular endpoints. The model included exposure to both statin and insulin
therapy. These were simply dichotomised as ever having at least two prescriptions dispensed
during the study period or never having had a prescription. Other variables included in the
model were smoking (recorded as ever smokers and never smokers) as well as a history of a
previous myocardial infarction. In this study a combined endpoint of fatal and non-fatal
myocardial infarction was used as determined by a hospital discharge event with myocardial
infarction as the diagnosis or cause of death being recorded as myocardial infarction. All
data manipulation and statistical analysis were executed using STATA v9.0
Results
The baseline characteristics of the 4897 Go-DARTS participants genotyped for FTO
rs9939609 who fulfilled the entry criteria for the study were are shown in table 1. The rare
(A) allele had a frequency of 0.424 SE 0.005. Allele frequencies at this locus in this
population did not deviate from Hardy-Weinberg equilibrium (p=0.96). Adjusted means by
FTO genotype for BMI, pulse pressure, mean arterial pressure, glycated hemoglobin, HDL
cholesterol, triglycerides, total cholesterol and atherogenic index of plasma are provided in
table 2. Inspection of the data indicated a dominant/co-dominant impact of the variant on all
clinical parameters investigated and therefore the significance levels for both models are
given. As expected there was a strong association of the FTO variant with BMI, with the
adjusted mean for individuals carrying the A allele (dominant model) being 0.77 kgm−2
greater than TT homozygotes (p=8.8×10−6). Similarly, the A allele was associated with an
adjusted mean HDL cholesterol that was 0.03 mmolL−1 lower (p=0.008) and an adjusted
mean triglyceride 0.1 mmolL−1 higher (p=0.002) compared to TT homozygotes. There was
no association of FTO with total cholesterol. Although individuals with the A allele were
more likely to be have been exposed to statin medication (p=0.002) (table 3), accounting for
this did not alter this lack of association. To further emphasise the atherogenicity of the lipid
profile we determined the atherogenic index15 and found that the A allele was associated
with a significantly higher index (0.03, p=0.003). We found no significant association of
genotype with glycated haemoglobin parameters or treatment with insulin (data not shown).
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The impact of FTO genotype on cardiovascular morbidity and mortality was modelled by
determining the relative hazard of possession of the A allele of rs9939609 for developing a
fatal or non-fatal myocardial infarction following recruitment in the 4101 individuals with
complete data. Age, gender, smoking status, prevalent myocardial infarction and having a
history of statin and insulin use were included in the initial model. The model included an
interaction term of genotype with statin use. During a mean follow-up of 3.6 years, there
were a total of 324 events with 94 (6.82%) occurring in the 1377 TT homozygotes and 230
(8.44%) in the 2724 individuals with the A allele. The hazard ratio for possession of the A
allele compared to TT homozygotes in this model was 2.36 CI 1.49-3.74, p=0.0002. With
the subsequent inclusion of obesity related parameters ie. BMI, glycated haemoglobin, mean
arterial pressure, HDL cholesterol, triglycerides and total cholesterol in the model the impact
of FTO genotype was reduced but remained significant (HR 2.01 CI 1.18-3.45, p=0.011). As
a result of the finding of a significant interaction term (p=0.001) for statin use by FTO
genotype we stratified the data according to statin use. Figure 1 gives the Kaplan-Meier
hazard functions for possession of the A allele compared to the TT homozygote in these two
groups showing that the increased risk is seen in the 1266 non-statin users (HR 2.3 CI
1.4-3.7, p=0.0005), but is abolished by statin use (HR 0.9 CI 0.7-1.3 p=0.64).
Discussion
We have demonstrated in this large prospective longitudinal study of patients with T2D that
variation in the FTO gene is not only associated with increased BMI, but also with a specific
dyslipidemic phenotype that is characteristic of insulin resistance. This in turn is associated
with an increase in risk of myocardial infarction and cardiovascular death. These
observations come from a population with established T2D, and the genotypic effect of the
FTO variant on lipids is therefore over and above the dyslipidemic profile and
cardiovascular risk we would expect in this population. This suggests that within the
spectrum of phenotypic subtypes of T2D the FTO variant is associated with one that is
marked by greater insulin resistance and at greater cardiovascular risk.
In determining metabolic phenotype we have been able to exploit the availability of multiple
measures over time in Go-DARTS to determine a mean value for an individual and in this
way accommodate the temporal fluctuation in single values that may obscure genuine
associations. The risk allele for increased weight and T2D is associated with a lower plasma
HDL cholesterol level, raised plasma triglycerides and therefore a raised atherogenic index,
and as expected this is largely driven by the effects of FTO on body weight. Interestingly the
FTO variant appears to be associated with overall fat mass in terms of both central
abdominal obesity and also subcutaneous fat3 and therefore not associated with a body fat
distribution typically associated with the insulin resistant state. On the other hand the clear
association with the risk of development of T2D implicates insulin resistance. Furthermore,
in a study of 1286 healthy individuals in whom diabetes had been excluded the FTO A allele
was found to be associated with peripheral insulin resistance8 as measured by
hyperinsulinemic euglycemic clamp. The insulin resistance however was again entirely
dependent on body weight.
Carriers of the FTO A allele were over twice as likely to have a myocardial infarction or
cardiovascular death than the TT homozygotes. The strength of this association appears to
be reduced although remains significant by including obesity-related parameters in the
model. This observation appears initially to be divergent from the association of FTO
genotype with T2D, which is completely explained by the effect of the FTO genotype on
BMI. In this case it is likely to be due to the correction of the obesity driven dyslipidemia in
the individuals who receive statins, thus disconnecting obesity risk from cardiovascular risk.
Doney et al. Page 4
Circ Cardiovasc Genet. Author manuscript; available in PMC 2011 February 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
This is consistent with previous observations that, for a similar cholesterol reduction statins
are more beneficial in patients who have a low HDL cholesterol and high triglyceride 16.
In this observational study the strong modulating influence of statin therapy with FTO
genotype-associated outcome raises several important questions. We chose the simple metric
of having had two prescriptions for a stain dispensed for pragmatic reasons given the known
significant impact statins have on cardiovascular event rates, however there are many
potential biases that could influence this metric. For example, we have demonstrated that the
risk allele of FTO was associated with a significantly higher level of prescribing of statins in
spite of no differences in cholesterol levels by genotype. However, no association was found
between cholesterol levels and FTO genotype in either individuals prescribed statins or
those not prescribed statins (data not shown) and thus the increased tendency to receive a
statin seems unlikely to be due to this indication in those carrying the risk allele. This
suggests that the increased statin prescribing may reflect other clinical aspects or risk
associated with the obese phenotype which is supported by the finding that this allele was
associated with significantly increased tendency to be prescribed other medications such as
the fibrates and thiazolidinedines (data not shown). This observation may therefore further
support the major finding of this study that FTO genotype is associated with a metabolic
phenotype which in turn is associated with greater cardiovascular risk. Thus the observed
impact of statins may be partly due to the fact that the more at risk individuals have a greater
number of protective medications being prescribed. In such an observational study such
potential biases are challenging to tease out and as such this finding would require to be
replicated in a randomised prospective study of statin use. It would also be appropriate to
consider replication of this finding in a non-diabetic population, however, given the assumed
biological association of this FTO variant with outcome is through an engendered metabolic
phenotype the event rate in the non-diabetic population is likely to be very low requiring
very large numbers of individuals. This is a likely reason that FTO has not been a striking
feature from GWAS of early-onset cardiovascular disease. At present the mechanism of
action of the FTO variant on increasing weight gain and increased insulin resistance is
uncertain. There are no features suggesting that rs9939609 is the causal variant and indeed
there are many other variants that are in complete linkage disequilibrium with this variant
and are therefore linked to obesity and diabetes. However, based on the rapid fall off of
linkage disequilibrium with other SNPs beyond 47-kb it has been concluded that the
functional variant is likely to lie within this area of the FTO gene3. Indeed rs8050136 has
recently been implicated in modulating the binding of a transcription factor CUTL1, and
CUTL1 knockdown by siRNA was shown to repress both FTO expression and expression of
the neighbouring gene FTM17. This SNP lies 4kb from rs9939609 and these variants are in
complete linkage disequilibrium in the Caucasian population (D’ of 1.00 and R2 of 0,996)3.
Through the use of bioinformatics and recombinant functional studies it has recently been
demonstrated that the FTO gene encodes a nucleic acid demethylase18,19. Although the
physiologically relevant substrate for this enzyme has yet to be determined, expression
appears to be highest in the brain and particularly in hypothalamic nuclei involved in energy
balance18. Furthermore expression was found to be modulated by feeding and fasting, and
correlated with the expression of various peptide hormones known to modulate eating
behaviour including Neuropeptide Y20. The neighbouring gene FTM which encodes a
ciliary protein, appears to be co-regulated with FTO in the arcuate nucleus and may also
play a role in the observed phenotypes17. This molecular data supports direct observations
from our own group that the eating behaviour of young children is modulated by FTO
genotype21. Indeed the FTO genotype has now been associated with weight gain from the
age of two weeks post birth22. This together with the present study clearly indicates that this
genotype is having a significant role in human health from the cradle to the grave, and
highlights recent concerns regarding the increased levels of childhood obesity and
subsequent cardiovascular morbidity and mortality23.
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Conclusion
We have demonstrated in a large group of patients with T2D that the A allele of rs9939609
in the FTO gene is associated not only with a raised BMI but also with a tendency to a
dyslipidemic phenotype seen typically in the insulin resistance syndrome. This translates
into an increased risk of myocardial infarction.
Prescription with statins appeared to ameliorate this association indicating that it is possible
for intervention to prevent the serious life threatening consequences of this genotype.
Common variation in the FTO gene has recently emerged as a major determinant of
human obesity. Obesity is in turn associated with an increased risk of developing Type 2
Diabetes with all its associated detriments to health. Recent evidence indicates that the
FTO gene regulates obesity by modulating food preference, with a recent study showing
that children, aged 7 to 9, eat 100 extra calories at a single meal when they carry a
particular FTO gene variant. These extra calories come from preferentially eating more
energy dense foods and may be mediated by differential regulation of hypothalamic gene
expression by the protein encoded by FTO. In the current report, a group of patients
being managed for Type 2 Diabetes who have inherited this same variant of the FTO
gene that is associated with overeating are on average even more obese and have an
unhealthier metabolic phenotype compared to patients not having this variant. This leads
in turn to a greater risk of myocardial infarction and death. Therefore, this gene has an
impact on individuals from early childhood through old age predisposing them to a
greater risk of ill health probably largely through the eating habits it engenders.
Interestingly we find that in patients who have been prescribed lipid lowering therapy in
the form of statins this association is not evident. This suggests that variation in the FTO
gene may contribute in the future to targeting specific therapies and interventions those
individuals at greatest risk.
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Fig 1.
Hazard functions for fatal and non-fatal myocardial infarction by FTO genotype in those
without satins (panel A) and those prescribed statins (panel B). Hazard ratios provided are
adjusted for age, gender, BMI, smoking status and history of myocardial infarction
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Table 1
Population characteristics
Mean SD
Age (yrs) 63.7 11.7
Female (%) 55.3 -
Prevalent MI (%) 10.9 -
Statin prescription (%) 69.8 -
Insulin Prescription (%) 32.4
BMI (kgm−2) 30.7 5.9
Systolic BP (mmHg) 140.9 7.8
Diastolic BP (mmHg) 77.7 7.7
Glycated Haemoglobin (%) 7.7 1.3
Triglycerides (mmolL−1) 2.4 1.6
Total cholesterol (mmolL−1) 4.8 0.9
HDL cholesterol (mmolL−1) 1.3 0.4
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Table 3
Individuals receiving a prescription for a statin during the course of the study in entire cohort
Statin Prescription TT TA/AA
No 478 (30%) 823 (25%)
Yes 1,140 (71%) 2,433 (75%)
Total 1,618 3,256
OR 1.24 CI 1.09-1.42 P=0.002
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